The contribution of founder mutations to early-onset breast cancer in French-Canadian women

Clinical Genetics

Volumn 76, Issue 5, 2009, Pages 421-426

  Ghadirian, P ^a   Robidoux, A ^a   Zhang, P ^b   Royer, R ^b   Akbari, M ^b   Zhang, S ^b   Fafard, E ^a   Costa, M ^a   Martin, G ^a   Potvin, C ^a   Patocskai, E ^a   Larouche, N ^a   Younan, R ^a   Nassif, E ^a   Giroux, S ^c   Narod, S A ^a   Rousseau, F ^c   Foulkes, W D ^d  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

BRCA1; BRCA2; Breast cancer; CHEK2; PALB2

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; ONCOPROTEIN; PALB2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANADA; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FOUNDER EFFECT; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; ONSET AGE; OVARY CANCER; PENETRANCE; POPULATION GENETICS; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; FOUNDER EFFECT; FRANCE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; QUEBEC; TUMOR SUPPRESSOR PROTEINS;

EID: 70449445707     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2009.01277.x     Document Type: Article

References (20)

1. Ford D, Easton DF, Stratton M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676-689.
2. Tonin P, Weber B, Offit K. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996, 2:1179-1183.
3. Warner E, Foulkes W, Goodwin P. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999, 91:1241-1247.
4. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302:643-646. New York Breast Cancer Study Group
5. Thorlacius S, Olafsdottir G, Tryggvadottir L. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996, 13:117-119.
6. Gorski B, Jakubowska A, Huzarski T. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004, 110:683-686.
7. Górski B, Cybulski C, Huzarski T. Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 2005, 92:19-24.
8. Tonin PM, Mes-Mason A-M, Futreal PA. Founder BRCA1 and BRCA2 mutations in French-Canadian breast and ovarian cancer families. Am J Hum Genet 1998, 63:1341-1351.
9. Simard J, Dumont M, Moisan A-M. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multi-step testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet 2007, 44:107-121.
10. Oros KK, Ghadirian P, Greenwood C. Significant proportion of breast and/or ovarian cancer families of French-Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer 2004, 112:411-419.
11. Zhang S, Phelan CM, Zhang P. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. Cancer Res 2008, 68:2154-2157.
12. Foulkes WD, Ghadirian P, Akbari MR. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 2007, 9:R83.
13. Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001, 29:E88-E88.
14. Tonin PN, Mes-Masson AM, Narod SA, Ghadirian P, Provencher D. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet 1999, 55:318-324.
15. Moisan AM, Fortin J, Dumont M. No evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families. Genet Test 2006, 10:104-115.
16. Offit K, Garber JE. Time to check CHEK2 in families with breast cancer?. J Clin Oncol 2008, 26:519-520.
17. Narod SA, Lynch HT. CHEK2 mutation and hereditary breast cancer. J Clin Oncol 2007, 25:6-7.
18. Gronwald J, Cybulski C, Piesiak WJ. Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband. Br J Cancer 2009, 100:1508-1512.
19. Cybulski C, Huzarski T, Byrski T. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. Clin Genet 2009, 75:72-78.
20. Erkko H, Dowty JG, Nikkilä J. Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res 2008, 14:4667-4671.